Clinical Research Studies

Improving the health of our patients through groundbreaking clinical research.

The Schweiger Dermatology Group (SDG) Clinical Research Department Research Clinic is led by Dr. David Goldberg, founder of Skin, Laser and Surgery Specialist of New York and New Jersey. Dr. Goldberg brings more than 25 years of experience in conducting large multi-center clinical trials on a wide variety of cosmetic and medical devices, as well as pharmaceutical treatments. Our research team is committed to responsible research conducted under strict industry and safety standards.

Current Dermatology Clinical Trials

Study: Injectable Treatment to Treat Keloids

Purpose: To assess the safety, tolerability, and efficacy of various doses of STP705 (10μg, 20μg, 30μg and 40μg) intradermal injection and placebo, when injected into the keloid excision site, to prevent the recurrence of keloids following their excision. The study treatments are administered once per week. There will be four (4) follow-up visits at one (1), three (3), six (6) and nine (9) months after your keloid surgery.

Qualifications:

  • Male and Females, 18 – 60 years old
  • Have at least one keloid scar present for at least one year on the upper body, arms, or legs

Duration: 54 weeks
Location: Hackensack, NJ
Compensation: Up to $1,100 if all study visits are completed

Interested in participating in our clinical research study? Please click here.


Study: Evaluation of the Mind.Px Patch on Response to Biologic Treatment for Patients with Plaque Psoriasis

Purpose: The purpose of this study is to evaluate the impact of Mind.Px on response to biologic treatment for patients suffering from plaque psoriasis, as judged by the mean change in the Psoriasis Area Severity index (PASI) score from baseline to end of Week 16 of the study.

Qualifications:

  • Male and Females, 18 years or older
  • Current diagnosis of Plaque Psoriasis

Duration: Up to 20 weeks
Locations: Hackensack, NJ
Compensation: Up to $630 will be paid to the patient *once all visits are completed*

Interested in participating in our clinical research study? Please click here.


Study: Evaluation of the risk of atrophic acne scar formation during treatment of acne vulgaris subjects with trifarotene 50 μg/g cream versus vehicle cream

Purpose: The purpose of this trial is to evaluate the effect of trifarotene 50 μg/g cream versus vehicle cream on the risk of formation of atrophic acne scars in facial acne subjects. This is a randomized, double-blind, vehicle-controlled clinical study using a split-face design for intra-individual comparison (right half-face versus left half-face).

Qualifications:

  • Male and Females, 17 to 35 years old
  • Clinical diagnosis of Acne Vulgaris on the face (minimum of 20 inflammatory lesions and minimum of 10 atrophic acne scars)
  • Symmetrical number of lesions/scars on the whole face (i.e. no more than twice as many lesions/scars of each type on one half of the face than on the other half)

Duration: Up to 24 weeks
Locations: Hackensack, NJ
Compensation: Up to $1,450

Interested in participating in our clinical research study? Please click here.


Study: Efficacy and Safety study of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis

Purpose: This study is being done to evaluate the safety and tolerability of RPT193 in subjects with moderate to severe atopic dermatitis, also known as eczema. Investigational product will be administered as monotherapy for AD in adult patients who have had an inadequate response to topical medications for AD (e.g., corticosteroids) or who are otherwise unable to take topical medications.

Qualifications:

  • Male and Females, 18 to 75 years old
  • Clinical diagnosis of Atopic Dermatitis
  • Documented history of inadequate response to a ≥1 month treatment with topical medications

Duration: Up to 7 months
Locations: Hackensack, NJ
Compensation: Up to $650

Interested in participating in our clinical research study? Please click here.


Study: A Post Market Study of a 1726nm Laser System for the Treatment of Acne Vulgaris

Purpose: The purpose of this investigation is to evaluate the safety and efficacy of the Cutera® 1726 nm laser system for the treatment of moderate to severe acne. Subjects will receive 3 laser treatments at 4-week intervals. Follow-up visits will occur at approximately 7 days post each treatment (via phone) and at 12-, 26- and 52-weeks post third treatment.

Qualifications:

  • Males and females, ages 16 to 60 years
  • Fitzpatrick skin types I-VI with moderate or severe acne vulgaris

Duration: Approximately 17 months
Locations: Hackensack, NJ
Compensation: Up to $275 will be paid to the patient *once all visits are completed*

Interested in participating in our clinical research study? Please click here.


Study: Non-Treatment Study for Hip Dip Images

Purpose: Participants will go through a 15-minute photo session of their Hip Dips at sponsor photography location. The images will be used for medical education or clinical research only.

Qualifications:

  • Females, ages 18 or older
  • BMI <27
  • No tattoos, prominent scarring, or excessive cellulite
  • Must be fully vaccinated

Duration: Approx. 15 minutes
Locations: Parsippany, NJ
Compensation: $200

Interested in participating in our clinical research study? Please click here.


Study: Phase 2 study to evaluate the efficacy and safety of RPT193 as monotherapy in adults with moderate-to severe atopic dermatitis (oral tablet)

Purpose: This study is being conducted to evaluate the clinical efficacy, safety and tolerability of RPT193 following oral multiple-dose, administration once a day, for 16 weeks to participants with moderate-to-severe Atopic Dermatitis. Atopic dermatitis is commonly known as eczema. The investigational product is given as a monotherapy for AD in adult participants who have had an inadequate response to topical medications given to them for AD or who are otherwise unable to use topical medications.

Qualifications:

    Qualification Criteria includes but is not limited to:

  • Adults age 18-75 years with a clinically confirmed diagnosis of AD
  • At least a 12 month history of AD with no significant flares in AD for at least 4 weeks before Screening
  • Documented history of inadequate response to a >1 month treatment with topical medication for AD (e.g. corticosteroids) or unable to use topical medications


Duration: Up to 7 months with about 10 visits
Locations: Verona, NJ
Compensation: $80 per completed site visit
Click here to view Q&A

Inquires can be sent to malgorzata.lasocha@schweigerderm.com
Interested in participating in our clinical research study? Please click here.

Interested in participating in our clinical research study?

Please click here


What to expect during a clinical trial:

  • Access to new investigational treatments before they are made widely available
  • Financial compensation for participation
  • An opportunity to contribute to the advancement of medical science through research
  • Study visits conducted by a trained and dedicated research team
  • Adherence to strict industry and safety standards.
  • Evaluations performed by one of our certified providers

To learn more contact: Diana Aranzazu, research@schweigerderm.com, 609-219-5621

About Schweiger Dermatology Group

Schweiger Dermatology Group was founded to help make excellent dermatology care accessible throughout the Northeast. In 2010, Dr. Eric Schweiger started the practice with a single location in Midtown Manhattan. When he saw the need for high-quality dermatology care that did not require weeks or months of waiting to see a qualified provider, his vision of a multi-location practice was born.

Back to Top
>

Receive skincare tips, news and special offers!

Field marked with asterisk (*) is mandatory.